Teleflex to Sell OEM Business in $1.5 Billion Cash Deal
The asset sale would sharpen Teleflex’s focus on higher-growth medical technologies while supporting debt reduction and shareholder returns.
Teleflex Incorporated (TFX) agreed to sell its OEM business to private-equity firms Montagu and Kohlberg for about $1.5 billion in cash, advancing a portfolio overhaul aimed at concentrating the medical-technology company on its core hospital markets. The transaction was structured as an asset purchase and remained subject to closing adjustments.
The companies expected the sale to close in the third quarter of 2026, subject to customary regulatory approvals and other closing conditions. The OEM transaction formed the larger piece of Teleflex’s planned $2.03 billion divestiture of three businesses; a separate agreement called for Intersurgical to acquire its Acute Care and Interventional Urology operations for about $530 million.
The divestiture would strengthen Teleflex's financial flexibility, accelerate investment in innovation and support sustainable, profitable growth while allowing it to return significant capital to shareholders. The remaining company would center on Vascular Access, Interventional and Surgical products, giving management a more focused portfolio and a simpler global operating and manufacturing structure.
The OEM operation supplied components and finished medical devices to other manufacturers and included the TFX Medical OEM, TFX OEM, Deknatel and HPC Medical brands. The business was a durable grower, with a 9.5% revenue compound annual growth rate from 2014 through 2023, although more recent performance had been affected by the loss of a legacy customer and customer inventory management.
The cash sale marked a change from Teleflex’s earlier plan to separate OEM, Urology and Acute Care into an independent publicly traded company. That proposal, announced in February 2025, contemplated a tax-free distribution to shareholders and was designed to give each company distinct investment priorities and capital-allocation strategies. The later agreements placed those businesses with strategic and financial buyers while preserving Teleflex’s objective of concentrating resources on higher-growth, high-acuity markets.
Teleflex expected approximately $1.8 billion in combined after-tax proceeds from the OEM and Intersurgical transactions. The company planned to direct much of that cash toward share repurchases and debt reduction under a capital plan that included a board-authorized repurchase program of as much as $1 billion. Teleflex had already moved up opportunistic repurchases to the second quarter of 2026, while maintaining its commitment to reduce leverage and preserve flexibility for future growth.